China deploys drones, insecticide, nets for mosquito-borne virus: Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Park Bom takes health break from 2NE1 group activities
8 Aug - Park Bom's camp recently announced that the singer will be taking a break from group activities with 2NE1 due to health issue. Sharing the news on 6 August, D-Nation Entertainment stated, "We are deeply saddened to deliver this news, especially as so many fans have shown their support for 2NE1's full-group activities." "Since medical staff recently advised that she needs sufficient rest and stability, we reached this unavoidable decision after careful discussion," they added. They also asked fans to give their support to Park Bom so that she can have good recovery. At the same time, the agency urged everybody to continue to show their love for Dara, CL and Minzy as they continue to perform without Park Bom. The 41-year-old singer was recently absent at the Waterbomb Busan 2025 Music Festival, where she was scheduled to perform on 26 July. She reunited with the rest of 2NE1 last year when they began performing to celebrate their 15th anniversary. (Photo Source: 2NE1 IG)
Yahoo
an hour ago
- Yahoo
Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests
Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring. HONG KONG, Aug. 8, 2025 /PRNewswire/ -- Codex Genetics, one of the leading precision diagnostics companies in Hong Kong, today announced an exclusive collaboration with Pacific Edge, the developer of the Cxbladder suite of non-invasive genomic urine tests, to bring its advanced bladder cancer diagnostics to hospitals and clinics across Hong Kong. Under this partnership, Codex Genetics will offer access to Cxbladder's full range of clinically validated tests—including Cxbladder Detect, Cxbladder Monitor, and Cxbladder Triage—designed to support urologists and oncologists in the risk stratification and surveillance of urothelial bladder cancer. These precision urine-based tests integrate genomic biomarker analysis with clinical algorithms to deliver actionable insights earlier in the patient care pathway. Importantly, following a February 2025 update, Cxbladder Triage is included in the Microhematuria Guideline[1] issued by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). The amended Guideline incorporates language supporting the use of urine-based biomarkers to reduce reliance on cystoscopy and Cxbladder Triage is mentioned specifically, supported with "Grade A" evidence from a randomized controlled trial – the STRATA study[2]. "Our collaboration with Cxbladder reflects Codex's continued commitment as a leading diagnostics company in Hong Kong to advance precision medicine across Asia," said Dr. Aldrin Yim, co-founder of Codex Genetics. "Bladder cancer is one of the most expensive cancers to manage due to its high recurrence rate and need for lifelong monitoring. By offering a reliable non-invasive alternative that can reduce the need for cystoscopy, we aim to enhance clinical workflows, allowing clinicians to prioritize time and resources on those who need it the most. This improves the quality of care for patients in both public and private healthcare systems." "We are excited to partner with Codex Genetics to expand access to Cxbladder in Hong Kong," said Dr. Peter Meintjes, CEO of Pacific Edge. "Codex's regional leadership in precision diagnostics makes them an ideal partner to deliver Cxbladder's value to clinicians and patients seeking reliable and less burdensome approaches to bladder cancer testing." Bladder cancer is the ninth most common cancer worldwide, with high recurrence contributing to its significant clinical and economic burden. Cxbladder has been used in over 100,000 patients globally and is supported by more than 25 peer-reviewed clinical studies demonstrating high sensitivity and negative predictive value. Its adoption can reduce the need for unnecessary invasive procedures and optimize clinical decision-making. Clinicians in Hong Kong interested in Cxbladder testing may contact Codex Genetics via for onboarding and access information. [1] Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. doi: 10.1097/JU.0000000000004490. [2] Lotan et al. (2024). A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212 1-8 Jul 2024. Contact:Whatsapp: (+852) 9837 1345Phone: (+852) 3008 2560Email: support@ View original content to download multimedia: SOURCE Codex Genetics Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Android Authority
an hour ago
- Android Authority
Samsung bashes Chinese watches, says it's already working on Galaxy Watch 9, 10
TL;DR Samsung recently compared its approach to smart wearables with Chinese fitness devices, claiming it focuses on 'high quality.' It said that Chinese smartwatches offer seven to ten days of battery backup because they offer low-power components. Samsung, on the other hand, is focusing on accurate health measurement systems that are already being tested for the next two generations of the Galaxy Watch. Samsung's Galaxy Watch 8 was launched just a month ago, but the company has already begun work on the Galaxy Watch 9 and Watch 10 models. At a press conference, a company executive recently drew a parallel between its products and Chinese competitors, highlighting how its approach differs from theirs. Samsung recently spoke to Korean media, where it said that it was focusing on user experience on its Galaxy Watch devices. Addressing competition from Chinese brands, Choi Jong-min, the executive director of Health Hardware Development Group, part of the Samsung Mobile Experience (MX) division, said that while Chinese brands are focusing on increasing market share by attracting new buyers. Samsung, on the other hand, is prioritizing improving longevity and working on better performance throughout the smartwatch's life. The executive's remarks, as shared by Korean outlet Sisa Journal, came in response to questions about progress made by Chinese brands in power-efficient systems. Likely referring to the likes of the Huawei Watch 5, Choi said these smartwatches use low-power chips with longer battery backup, of seven to ten days. He might also be referring to the dual-chip dual-OS approach taken by OPPO and OnePlus for their identical smartwatches. But the lower power consumption of these chips, Choi pointed out, is also contributing to poorer performance. Meanwhile, Samsung's focus, as per the executive, has been on improving the accuracy of health features. With the Galaxy Watch 8, Samsung offers a new metric called Antioxidant Index, which detects the amount of carotenoids — a class of organic compounds present in certain yellow fruits, vegetables, and eggs, whose low levels can serve as markers for cancer. Additionally, the Galaxy Watch 8 infers Vascular Load, which quantifies the amount of stress while you sleep and can determine the quality and impact of your sleep more than the number of hours you slept. This is accomplished through a sophisticated biosensor, which has been improved on the Galaxy Watch 8 series over previous generations. In addition to highlighting the carotenoid measurement, Choi noted this was a result of more than five years of research. Adding that the company is planning up to five years in advance, he said the team is already working on reviewing features for the Galaxy Watch 9 and Watch 10 models. Follow
